Share

December 2021; 11 (6) ResearchOpen Access

Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1

Stephanie M. Morris, Aditi Gupta, Seunghwan Kim, Randi E. Foraker, David H. Gutmann, Philip R.O. Payne
First published April 14, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001089
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
666

Share

Article Information

vol. 11 no. 6 e497-e505
DOI: 
https://doi.org/10.1212/CPJ.0000000000001089
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received August 6, 2020
  • Accepted February 25, 2021
  • First Published April 14, 2021.

Article Versions

Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Stephanie M. Morris, MD*,
    2. Aditi Gupta, PhD*,
    3. Seunghwan Kim, MS,
    4. Randi E. Foraker, PhD, MA,
    5. David H. Gutmann, MD, PhD and
    6. Philip R.O. Payne, PhD
  1. Stephanie M. Morris, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Springworks Therapeutics - consultant

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) NIH, 5K12NS00169017, trainee, 2015-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Aditi Gupta, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Centene Corporation contract (P19-00559) for the Washington University-Centene ARCH Personalized Medicine Initiative.

    Research Support, Government Entities:

    1. (1) NCATS, IDDRC Collaborative Innovation Award U01, Project Manager, 2020-2024 (2) NIH/NHGRI 5R01HG00935104, Researcher, 2017-2021 Stock/Stock Options, Medical Equipment & Materials: My husband has stocks in (1) Cigna (2) TherapeuticsMD (3) Ocugen, Inc.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Seunghwan Kim, MS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Centene Corporation contract (P19-00559) for the Washington University-Centene ARCH Personalized Medicine Initiative.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Randi E. Foraker, PhD, MA,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Current Epidemiology Reports, Cardiovasular Disease Section Editor, 2018- present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH/NCI, 1R01CA226078, MPI, 2018-2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Global Autoimmune Institute

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. David H. Gutmann, MD, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Glia Neuro-Oncology

    Patents:

    1. NF1 Gene, 1999. Identification of the NF1 gene and protein. mTOR, 2012. Identification of NF1 protein as mTOR regulator.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. PI, NCI, R01, Defining risk factors for NF1-optic glioma, 2016-2021 PI, NIH, Defining the mechanistic basis for neurofibromatosis-1 nervous system disease heterogeneity. 2016-2024.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. PD, The Giorgio Foundation, NF1-Dermal Neurofibroma Consortium, 2016-2021 PI, Neurofibromatosis Therapeutic Acceleration Program, Leveraging human iPSCs to determine the impact of patient-derived NF1 gene mutations on peripheral sensory neuron-driven Schwann cell growth, 2018-2021 PI, Gilbert Family Foundation, Vision Restoration Initiative, 2019-2022 PI, PLGA, Human iPSC PLGA Models for Therapeutic Drug Discovery and Evaluation, 2020-2022

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. TSC knockout (GFAP-Cre) mouse (Tuberous Sclerosis Alliance)

    Royalty Payments, Technology or Inventions:

    1. NF1 gene patent, University of Michigan, 2000 to 2015

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Philip R.O. Payne, PhD
    7. Scientific Advisory Boards:

    1. (1) Geisinger Health

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. (1) BMC Medical Informatics and Decision Making, Section Editor (Healthcare Information Technology, 2016-2020, (2) JAMIA Open, Associate Editor, 2018-Present

    Patents:

    1. NONE

    Publishing Royalties:

    1. Payne PR and Embi PJ, Editors. Translational Informatics: Realizing the Promise of Knowledge-driven Healthcare, 1st Edition. Springer. 2015.

    Employment, Commercial Entity:

    1. (1) Centene Corporation contract (P19-00559) for the Washington University-Centene ARCH Personalized Medicine Initiative.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NCI, Cancer Center Support Grant, Co-I, 2020-2025, (2) NCATS, National Center for Digital Health Informatics Innovation (CD2H) U24, Site PI, 2017-2022, (3) NCATS, The Washington University Institute for Clinical and Translational Science UL1, Co-I, 2017-2022, (4) NCI, Assessing Efficacy and Implementation of an EHR Tool to Assess Heart Health Among Cancer Survivors R01, Co-I, 2018-2022, (5) NCATS, IDDRC Collaborative Innovation Award U01, Co-I, 2020-2024, (6) NCATS, Instrumenting the Delivery System for a Genomics Research Information Commons (GRIN) U01, Site PI, 2019-2024, (7) NCATS, National COVID Cohort Collaborative (N3C) Administrative Supplement, Site PI, 2020-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. (1) TRIAD (Translational Research Informatics and Data Management Grid), OSU Innovation Foundation

    Royalty Payments, Technology or Inventions:

    1. (1) TRIAD (Translational Research Informatics and Data Management Grid), OSU Innovation Foundation

    Stock/Stock Options, Research Sponsor:

    1. (1) Signet, LLC, 2014-Present, (2) Aver, Inc, 2012-Present

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (DHG), Washington University, St. Louis, MO; and Institute for Informatics (SMM, AG, SK, REF, PROP), Washington University, St. Louis, MO.
  1. Correspondence
    Dr. Payne prpayne{at}wustl.edu
View Full Text

Article usage

Article usage: April 2021 to December 2022

AbstractFullPdfSource
Apr 202184021Highwire
May 202154014Highwire
Jun 202145011Highwire
Jul 202172018Highwire
Aug 202138016Highwire
Sep 20213109Highwire
Oct 202149039Highwire
Nov 202123021Highwire
Dec 20211733838Highwire
Jan 202217223100Highwire
Feb 20221710555Highwire
Mar 20222118339Highwire
Apr 2022715861Highwire
May 2022109440Highwire
Jun 202279426Highwire
Jul 202258921Highwire
Aug 2022357929Highwire
Sep 202248836Highwire
Oct 202295520Highwire
Nov 2022710837Highwire
Dec 202265715Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me